Roivant Sciences Aktie - ROIV

Rendering Error

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

10,105

Gebot

10,10

Fragen

10,11

Volumen

4.774.083

9,92 Tagesbereich 10,22

9,96 52-Wochen-Bereich 13,055

Marktkapitalisierung

7,21B

Handelsende

10,38

Handelsbeginn

10,18

Letzte Trade

100

10.105

Letzter Handelszeitpunkt

21:56:29

Finanzvolumen

US$ 48.100.992

VWAP

10,0754

Durchschnittliches Volumen (3 Mio.)

5.268.329

Ausgegebene Aktien

713.549.458

Dividendenrendite

Kurs-Gewinn-Verhältnis

1,67

Gewinn pro Aktie (EPS)

6,09

Erlöse

124,8M

Nettogewinn

4,35B

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.roivant.com

Hauptsitz

Hamilton, Bmu

Gegründet

Roivant Sciences Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ROIV. The last closing price for Roivant Sciences was US$10,38. Over the last year, Roivant Sciences shares have traded in a share price range of US$ 9,96 to US$ 13,055.

Roivant Sciences currently has 713.549.458 shares in issue. The market capitalisation of Roivant Sciences is US$7,41 billion. Roivant Sciences has a price to earnings ratio (PE ratio) of 1.67.

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks...

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology...

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE...

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant...

Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board

BASEL, Switzerland and LONDON and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (“Roivant”) today announced that the members...

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today...

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zest Health, the first value-based virtual care company focused on treating patients with...

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today...

Form 4 - Statement of changes in beneficial ownership of securities

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.695	-6.43518518519	10.8	10.905	10.085	5738953	10.58700608	CS
4	-0.69	-6.39184807781	10.795	11.415	9.96	7007594	10.6777029	CS
12	-1.585	-13.5585970915	11.69	11.815	9.96	5268329	10.77023962	CS
26	-1.305	-11.4373356705	11.41	12.935	9.96	4892836	11.30222673	CS
52	-0.415	-3.94486692015	10.52	13.055	9.96	5355911	11.28099934	CS
156	5.405	115	4.7	13.24	2.52	4141337	10.22707786	CS
260	0.605	6.36842105263	9.5	16.76	2.52	3633421	10.18625109	CS

ROIV - Frequently Asked Questions (FAQ)

What is the current Roivant Sciences share price?

The current share price of Roivant Sciences is US$ 10,105

How many Roivant Sciences shares are in issue?

Roivant Sciences has 713.549.458 shares in issue

What is the market cap of Roivant Sciences?

The market capitalisation of Roivant Sciences is USD 7,41B

What is the 1 year trading range for Roivant Sciences share price?

Roivant Sciences has traded in the range of US$ 9,96 to US$ 13,055 during the past year

What is the PE ratio of Roivant Sciences?

The price to earnings ratio of Roivant Sciences is 1,67

What is the cash to sales ratio of Roivant Sciences?

The cash to sales ratio of Roivant Sciences is 58,09

What is the reporting currency for Roivant Sciences?

Roivant Sciences reports financial results in USD

What is the latest annual turnover for Roivant Sciences?

The latest annual turnover of Roivant Sciences is USD 124,8M

What is the latest annual profit for Roivant Sciences?

The latest annual profit of Roivant Sciences is USD 4,35B

What is the registered address of Roivant Sciences?

The registered address for Roivant Sciences is CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON, D0 HM11

What is the Roivant Sciences website address?

The website address for Roivant Sciences is www.roivant.com

Which industry sector does Roivant Sciences operate in?

Roivant Sciences operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AAGRAfrican Agriculture Holdings Inc	US$ 0,00 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0,00 (0,00%)	0
AADIAadi Bioscience Inc	US$ 0,00 (0,00%)	0
AACGATA Creativity Global	US$ 0,00 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 0,00 (0,00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0,00 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0,00 (0,00%)	0
AADIAadi Bioscience Inc	US$ 0,00 (0,00%)	0
AACGATA Creativity Global	US$ 0,00 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 0,00 (0,00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0,00 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0,00 (0,00%)	0
AADIAadi Bioscience Inc	US$ 0,00 (0,00%)	0
AACGATA Creativity Global	US$ 0,00 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 0,00 (0,00%)	0

Rendering Error

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roivant Sciences Ltd (ROIV) Börsenkurse

Roivant Sciences Ltd (ROIV)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Roivant Sciences Ltd

ROIV Neueste Nachrichten

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

ROIV - Frequently Asked Questions (FAQ)

Beweger

ROIV Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen